Open AccessAn observational study of a cohort of citizens receiving the AZD1222 vaccine against SARS-CoV-2
Author(s) -
C. Pellegrino,
Annachiara Coppola,
Biancamaria Pierri,
Palmiero Volzone,
Dario Bruzzese,
Andrea Pierri,
Amedeo Ferro,
Daniela Schiavi,
Antonio Coppola,
Stefano Miniero,
Luigi Atripaldi,
Caterina Pirozzi,
Pasquale Rusciano,
Alessandra Macri,
Rita Boenzi,
Silvia Sale,
Gianfranco Brambilla,
Carlo Buonerba
Publication year - 2021
Publication title -
future science oa
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.825
H-Index - 23
ISSN - 2056-5623
DOI - 10.2144/fsoa-2021-0064
Subject(s) - medicine , adverse effect , incidence (geometry) , cohort , thrombosis , retrospective cohort study , aspirin , cohort study , observational study , emergency medicine , intensive care medicine , optics , physics
In this retrospective study, a cohort of 67 subjects vaccinated with AZD1222 was retrospectively observed. Consistently with published findings, no serious adverse event was reported, and all adverse events reported (fever, muscle ache and/or pain in the site of injection) had resolved by day 8. Of note, some citizens were prescribed low-dose aspirin and even heparin for thrombosis prevention. We also found variations in laboratory test results (full blood count and chemistry) on day 1 compared with day 8. Physicians should be aware that no prevention therapy for thrombosis is currently recommended, given the very low incidence of this side effect. Additional studies are warranted to interpret our findings.